A Phase III Randomized Study Comparing a Chemotherapy with Cisplatin and Etoposide to a Etoposide Regimen without Cisplatin for Patients with Extensive Small-Cell Lung Cancer

INTRODUCTION: In a literature meta-analysis, we showed survival benefits for regimens including cisplatin [hazard ratio (HR) 0.61; 95% confidence interval (CI), 0.57–0.66] and for those including etoposide (HR 0.65; 0.61–0.69). That benefit was mainly observed when etoposide alone or in combination...

Descripción completa

Detalles Bibliográficos
Autores principales: Berghmans, Thierry, Scherpereel, Arnaud, Meert, Anne-Pascale, Giner, Vicente, Lecomte, Jacques, Lafitte, Jean-Jacques, Leclercq, Nathalie, Paesmans, Marianne, Sculier, Jean-Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610723/
https://www.ncbi.nlm.nih.gov/pubmed/28975084
http://dx.doi.org/10.3389/fonc.2017.00217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5610723/
https://www.ncbi.nlm.nih.gov/pubmed/28975084
http://dx.doi.org/10.3389/fonc.2017.00217

Ejemplares similares